Effect of epidermal growth factor on non-steroidal anti-inflammatory drug-induced intestinal damage

1989 ◽  
Vol 27 (3-4) ◽  
pp. 294-296 ◽  
Author(s):  
J. F. DiJoseph ◽  
C. L. Wells
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Intestinal Damage ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Epidermal Growth ◽  
Anti Inflammatory

scholarly journals Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion.

Gut ◽  
1994 ◽  
Vol 35 (5) ◽  
pp. 611-614 ◽  
Author(s):  
S M Kelly ◽  
J R Jenner ◽  
R J Dickinson ◽  
J O Hunter
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Gastric Juice ◽  
Inflammatory Drug ◽  
Drug Ingestion ◽  
Epidermal Growth ◽  
Anti Inflammatory

scholarly journals Involvement of gliadin, a component of wheat gluten, in increased intestinal permeability leading to non-steroidal anti-inflammatory drug-induced small-intestinal damage

PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0211436 ◽  
Author(s):  
Sunao Shimada ◽  
Tetsuya Tanigawa ◽  
Toshio Watanabe ◽  
Akinobu Nakata ◽  
Naoki Sugimura ◽  
...  
Keyword(s):  
Intestinal Permeability ◽  
Wheat Gluten ◽  
Intestinal Damage ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Small Intestinal ◽  
Anti Inflammatory

Mo1031 PROTECTIVE ROLE OF THE PRO-RESOLVING LIPID MEDIATOR RESOLVIN D1 IN NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED SMALL INTESTINAL DAMAGE

2020 ◽  
Vol 158 (6) ◽  
pp. S-762
Author(s):  
Takuya Kuzumoto ◽  
Tetsuya Tanigawa ◽  
Hiroyuki Kitamura ◽  
Akira Higashimori ◽  
Yuji Nadatani ◽  
...  
Keyword(s):  
Protective Role ◽  
Lipid Mediator ◽  
Intestinal Damage ◽  
Resolvin D1 ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Small Intestinal ◽  
Anti Inflammatory

Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage

2013 ◽  
Vol 45 (5) ◽  
pp. 390-395 ◽  
Author(s):  
Toshio Watanabe ◽  
Tetsuya Tanigawa ◽  
Yuji Nadatani ◽  
Yasuaki Nagami ◽  
Satoshi Sugimori ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intestinal Damage ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Small Intestinal ◽  
Anti Inflammatory

scholarly journals Epiregulin Is Not Essential for Development of Intestinal Tumors but Is Required for Protection from Intestinal Damage

2004 ◽  
Vol 24 (20) ◽  
pp. 8907-8916 ◽  
Author(s):  
Daekee Lee ◽  
R. Scott Pearsall ◽  
Sanjoy Das ◽  
Sudhansu K. Dey ◽  
Virginia L. Godfrey ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Dextran Sulfate ◽  
Dextran Sulfate Sodium ◽  
Cancer Susceptibility ◽  
Intestinal Damage ◽  
Developmental Defects ◽  
Epithelial Cell Lines ◽  
Epidermal Growth ◽  
Altered Liver

ABSTRACT Epiregulin, an epidermal growth factor family member, acts as a local signal mediator and shows dual biological activity, stimulating the proliferation of fibroblasts, hepatocytes, smooth muscle cells, and keratinocytes while inhibiting the growth of several tumor-derived epithelial cell lines. The epiregulin gene (Ereg) is located on mouse chromosome 5 adjacent to three other epidermal growth factor family members, epigen, amphiregulin, and betacellulin. Gene targeting was used to insert a lacZ reporter into the mouse Ereg locus and to ablate its function. Although epiregulin is broadly expressed and regulated both spatially and temporally, Ereg null mice show no overt developmental defects, reproductive abnormalities, or altered liver regeneration. Additionally, in contrast to previous hypotheses, Ereg deficiency does not alter intestinal cancer susceptibility, as assayed in the ApcMin model, despite showing robust expression in developing tumors. However, Ereg null mice are highly susceptible to cancer-predisposing intestinal damage caused by oral administration of dextran sulfate sodium.

Sign in / Sign up

Export Citation Format

Share Document